Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs

*Department of Pathology, Belfast Health and Social Care Trust, Belfast

#The Royal Marsden Hospital NHS Trust, London, UK

†Molecular Mechanisms and Experimental Therapy in Oncology Program, Bellvitge Biomedical Research Institute, Idibell

**Genomics Medicine Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Navarra, Spain

‡Gerald Bronfman Department of Oncology

∥∥Department of Human Genetics, McGill University, Montréal, QC

§Department of Laboratory Medicine and Pathobiology, University of Toronto, University Health Network, Toronto, ON

††Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

∥International Pleuropulmonary Blastoma (PPB)/DICER1 Registry, Cancer and Blood Disorders, Children’s Minnesota, Minneapolis, MN

¶Lauren V. Ackerman Laboratory of Surgical Pathology, St. Louis Children’s Hospital, Washington University Medical Center, St. Louis, MO

‡‡Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany

§§Department of Histopathology, King Edward Memorial Hospital, Perth, WA, Australia

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: W. Glenn McCluggage, FRCPath, Department of Pathology, Belfast Health and Social Care Trust, Grosvenor Road, Belfast BT12 6BA, UK (e-mail: [email protected]).

留言 (0)

沒有登入
gif